Progress in Slowing Cognition Losses
Eli Lilly said its solanezumab Alzheimer's drug failed to meet primary endpoints in two studies. The good news, however, is that data pooled across the trials showed a statistically significant slowing of cognitive decline in some patients studied. Investors are focusing on that positive news, and LLY is up by 9 percent before the bell on my tradeMONSTER platform.
Aruba Networks Rallies on Strong Results
Aruba Networks reported fourth quarter earnings of $0.18 a share, one penny better than the $0.19 forecast by Street analysts. Revenue of $139.2 million also surpassed the $136.82 million consensus estimate. ARUN climbs more than 13 percent in early trading.
Autodesk Plunges After Earnings, Revenue Miss
Autodesk earned $0.48, missing the $0.49 expected by analysts. Revenue was even worse at just $568.7 million versus the $568.7 million estimate. Management also reduced its full-year revenue outlook. ADSK plunges 22 percent in the premarket.